Jun 09, 2021 / 06:10PM GMT
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD
Great. Good afternoon, everybody. I'm Terence Flynn, the U.S. biopharma analyst at Goldman Sachs. And thank you for joining us at our virtual conference. I'm very pleased to be hosting Gilead Sciences.
Today from the company, we have Andy Dickinson, who is the company's Chief Financial Officer. Andy, thanks so much for taking the time today to join us out of your busy day. Really appreciate it.
Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO
No, I'm happy to do it. Thanks for having us.
Questions and Answers:
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MDSo I think maybe just at a high level, I think one of the key questions that people are focused on here for Gilead is just the longer-term outlook on the growth side. And so as you think about the outlook there, what gives you the confidence that the company is positioned here to grow on a forward and a sustainable basis, Andy?
Trustpilot
